http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 13 Oct 2026 02:38:26 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Downgrades/Evercore+ISI+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+In+Line/27175756.html <p>Evercore ISI analyst Gavin Clark-Gartner downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to In Line with a price target of $3.00 (from $14.00).</p><p>The analyst comments: “Unfortunately, ’909 failed to deliver on efficacy and FHTX/LLY have decided not to progress the program forward. Management relayed that ’909 seemed to cover the target with a favorable safety window, but the biology/preclinical didn’t translate. Sad outcome, but absolutely worth testing the hypothesis. Both ’909 and the separate selective SMARCA2 degrader are being discontinued. Also assume ARID (another BAF complex subunit) will be an uphill battle here.</p><p>We’ve updated our model and new PT = http://www.streetinsider.com/Downgrades/Evercore+ISI+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+In+Line/27175756.html Tue, 13 Oct 2026 02:38:26 -0400 FHTX http://www.streetinsider.com/Analyst+Comments/Evercore+ISI+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+In+Line/27175756.html <p>Evercore ISI analyst Gavin Clark-Gartner downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to In Line with a price target of $3.00 (from $14.00).</p><p>The analyst comments: “Unfortunately, ’909 failed to deliver on efficacy and FHTX/LLY have decided not to progress the program forward. Management relayed that ’909 seemed to cover the target with a favorable safety window, but the biology/preclinical didn’t translate. Sad outcome, but absolutely worth testing the hypothesis. Both ’909 and the separate selective SMARCA2 degrader are being discontinued. Also assume ARID (another BAF complex subunit) will be an uphill battle here.</p><p>We’ve updated our model and new PT = http://www.streetinsider.com/Analyst+Comments/Evercore+ISI+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+In+Line/27175756.html Tue, 13 Oct 2026 02:38:26 -0400 FHTX http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Foghorn+Therapeutics++++++For%3A+Oct+01++Filed+by%3A+BVF+II+GP+LLC/27149164.html si-local-file:///var/storage/secattach/20261005/27149164.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Foghorn+Therapeutics++++++For%3A+Oct+01++Filed+by%3A+BVF+II+GP+LLC/27149164.html Mon, 05 Oct 2026 16:28:00 -0400 FHTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/27149152.html si-local-file:///var/storage/secattach/20261005/27149152.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/27149152.html Mon, 05 Oct 2026 16:27:00 -0400 FHTX http://www.streetinsider.com/Downgrades/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html (Updated - October 2, 2026 6:55 AM EDT) <p>Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to Neutral with a price target of $2.00 (from $10.00)</p><p>The analyst comments "FHTX and Lilly have elected not to advance FHD-909 or the selective SMARCA2 degrader following a review of Phase 1 dose escalation data, ending the collaboration and the primary driver of our thesis; we are downgrading to NEUTRAL and revising our PT to $2 (from $10), to reflect cash on hand. Per today's disclosure, FHD-909 achieved on-target SMARCA2 engagement with a favorable safety profile at exposures exceeding preclinical benchmarks; however, http://www.streetinsider.com/Downgrades/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html Fri, 02 Oct 2026 06:55:54 -0400 FHTX LLY http://www.streetinsider.com/Analyst+PT+Change/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html (Updated - October 2, 2026 6:55 AM EDT) <p>Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to Neutral with a price target of $2.00 (from $10.00)</p><p>The analyst comments "FHTX and Lilly have elected not to advance FHD-909 or the selective SMARCA2 degrader following a review of Phase 1 dose escalation data, ending the collaboration and the primary driver of our thesis; we are downgrading to NEUTRAL and revising our PT to $2 (from $10), to reflect cash on hand. Per today's disclosure, FHD-909 achieved on-target SMARCA2 engagement with a favorable safety profile at exposures exceeding preclinical benchmarks; however, http://www.streetinsider.com/Analyst+PT+Change/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html Fri, 02 Oct 2026 06:55:54 -0400 FHTX LLY http://www.streetinsider.com/Analyst+Comments/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html (Updated - October 2, 2026 6:55 AM EDT) <p>Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to Neutral with a price target of $2.00 (from $10.00)</p><p>The analyst comments "FHTX and Lilly have elected not to advance FHD-909 or the selective SMARCA2 degrader following a review of Phase 1 dose escalation data, ending the collaboration and the primary driver of our thesis; we are downgrading to NEUTRAL and revising our PT to $2 (from $10), to reflect cash on hand. Per today's disclosure, FHD-909 achieved on-target SMARCA2 engagement with a favorable safety profile at exposures exceeding preclinical benchmarks; however, http://www.streetinsider.com/Analyst+Comments/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html Fri, 02 Oct 2026 06:55:54 -0400 FHTX LLY http://www.streetinsider.com/Downgrades/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html (Updated - October 2, 2026 6:55 AM EDT) <p>Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to Neutral with a price target of $2.00 (from $10.00)</p><p>The analyst comments "FHTX and Lilly have elected not to advance FHD-909 or the selective SMARCA2 degrader following a review of Phase 1 dose escalation data, ending the collaboration and the primary driver of our thesis; we are downgrading to NEUTRAL and revising our PT to $2 (from $10), to reflect cash on hand. Per today's disclosure, FHD-909 achieved on-target SMARCA2 engagement with a favorable safety profile at exposures exceeding preclinical benchmarks; however, http://www.streetinsider.com/Downgrades/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html Fri, 02 Oct 2026 06:55:54 -0400 FHTX LLY http://www.streetinsider.com/Analyst+PT+Change/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html (Updated - October 2, 2026 6:55 AM EDT) <p>Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to Neutral with a price target of $2.00 (from $10.00)</p><p>The analyst comments "FHTX and Lilly have elected not to advance FHD-909 or the selective SMARCA2 degrader following a review of Phase 1 dose escalation data, ending the collaboration and the primary driver of our thesis; we are downgrading to NEUTRAL and revising our PT to $2 (from $10), to reflect cash on hand. Per today's disclosure, FHD-909 achieved on-target SMARCA2 engagement with a favorable safety profile at exposures exceeding preclinical benchmarks; however, http://www.streetinsider.com/Analyst+PT+Change/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html Fri, 02 Oct 2026 06:55:54 -0400 FHTX LLY http://www.streetinsider.com/Analyst+Comments/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html (Updated - October 2, 2026 6:55 AM EDT) <p>Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to Neutral with a price target of $2.00 (from $10.00)</p><p>The analyst comments "FHTX and Lilly have elected not to advance FHD-909 or the selective SMARCA2 degrader following a review of Phase 1 dose escalation data, ending the collaboration and the primary driver of our thesis; we are downgrading to NEUTRAL and revising our PT to $2 (from $10), to reflect cash on hand. Per today's disclosure, FHD-909 achieved on-target SMARCA2 engagement with a favorable safety profile at exposures exceeding preclinical benchmarks; however, http://www.streetinsider.com/Analyst+Comments/Wedbush+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27138717.html Fri, 02 Oct 2026 06:55:54 -0400 FHTX LLY http://www.streetinsider.com/Analyst+PT+Change/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+H.C.+Wainwright/27138726.html (Updated - October 2, 2026 6:54 AM EDT) <p>H.C. Wainwright analyst Andrew Fein lowered the price target on Foghorn Therapeutics (NASDAQ: FHTX) to $5.00 (from $13.00) while maintaining a Buy rating.</p><p>The analyst commented: "Yesterday, Foghorn announced the discontinuation of the Lilly-partnered (LLY, not rated) FHD-909 program following review of clinical data from the Phase 1 dose escalation. While FHD-909 demonstrated favorable safety at exposures exceeding preclinical targets, the SMARCA2/4 synthetic lethality relationship did not translate into a level of efficacy warranting further clinical development. The collaboration between Foghorn and Lilly will also not be advancing the selective SMARCA2 degrader program and http://www.streetinsider.com/Analyst+PT+Change/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+H.C.+Wainwright/27138726.html Fri, 02 Oct 2026 06:54:42 -0400 FHTX http://www.streetinsider.com/Analyst+Comments/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+H.C.+Wainwright/27138726.html (Updated - October 2, 2026 6:54 AM EDT) <p>H.C. Wainwright analyst Andrew Fein lowered the price target on Foghorn Therapeutics (NASDAQ: FHTX) to $5.00 (from $13.00) while maintaining a Buy rating.</p><p>The analyst commented: "Yesterday, Foghorn announced the discontinuation of the Lilly-partnered (LLY, not rated) FHD-909 program following review of clinical data from the Phase 1 dose escalation. While FHD-909 demonstrated favorable safety at exposures exceeding preclinical targets, the SMARCA2/4 synthetic lethality relationship did not translate into a level of efficacy warranting further clinical development. The collaboration between Foghorn and Lilly will also not be advancing the selective SMARCA2 degrader program and http://www.streetinsider.com/Analyst+Comments/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+H.C.+Wainwright/27138726.html Fri, 02 Oct 2026 06:54:42 -0400 FHTX http://www.streetinsider.com/Analyst+PT+Change/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+Guggenheim/27138705.html (Updated - October 2, 2026 6:48 AM EDT) <p>Guggenheim analyst Michael Schmidt lowered the price target on Foghorn Therapeutics (NASDAQ: FHTX) to $5.00 (from $12.00) while maintaining a Buy rating.</p><p>The analyst commented: "FHTX announced that they and partner LLY will not be advancing FHD-909 (SMARCA2 inhibitor) based on the Phase 1 clinical data generated to date, with cessation of collaboration activities, including development of the selective SMARCA2 degrader program, as well as a 40% RIF. This is disappointing news, given FHD-909 was the company's lead value driver and most advanced program in clinical development. Recall, FHTX was evaluating FHD-909 in partnership http://www.streetinsider.com/Analyst+PT+Change/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+Guggenheim/27138705.html Fri, 02 Oct 2026 06:48:35 -0400 FHTX http://www.streetinsider.com/Analyst+Comments/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+Guggenheim/27138705.html (Updated - October 2, 2026 6:48 AM EDT) <p>Guggenheim analyst Michael Schmidt lowered the price target on Foghorn Therapeutics (NASDAQ: FHTX) to $5.00 (from $12.00) while maintaining a Buy rating.</p><p>The analyst commented: "FHTX announced that they and partner LLY will not be advancing FHD-909 (SMARCA2 inhibitor) based on the Phase 1 clinical data generated to date, with cessation of collaboration activities, including development of the selective SMARCA2 degrader program, as well as a 40% RIF. This is disappointing news, given FHD-909 was the company's lead value driver and most advanced program in clinical development. Recall, FHTX was evaluating FHD-909 in partnership http://www.streetinsider.com/Analyst+Comments/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+Guggenheim/27138705.html Fri, 02 Oct 2026 06:48:35 -0400 FHTX http://www.streetinsider.com/Downgrades/BTIG+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27136680.html <p>BTIG analyst Jeet Mukherjee downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Buy to Neutral.</p><p>For an analyst ratings summary and ratings history on Foghorn Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=FHTX">click here</a>. For more ratings news on Foghorn Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FHTX&amp;type=analyst">click here</a>.</p><p>Shares of Foghorn Therapeutics closed at $3.57 yesterday.</p> http://www.streetinsider.com/Downgrades/BTIG+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Neutral/27136680.html Thu, 01 Oct 2026 16:38:10 -0400 FHTX http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Hold/27135958.html (Updated - October 1, 2026 4:08 PM EDT) <p>TD Cowen analyst Yaron Werber downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Buy to Hold.</p><p>The analyst comments "We are downgrading FHTX stock to Hold after this morning’s decision by Foghorn and Lilly not to advance FHD-909 into dose expansion, which in turn winds down the collaboration. While disappointing, we believe Foghorn executed well and developed a high-quality SMARCA2 inhibitor that achieved favorable safety and exposure. In our callback, mgmt described the result as unambiguous but more reflective of SMARCA2/4 as a poor target for synthetic lethality. Hence, the collaboration will also not advance a http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Hold/27135958.html Thu, 01 Oct 2026 16:08:35 -0400 FHTX http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Hold/27135958.html (Updated - October 1, 2026 4:08 PM EDT) <p>TD Cowen analyst Yaron Werber downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Buy to Hold.</p><p>The analyst comments "We are downgrading FHTX stock to Hold after this morning’s decision by Foghorn and Lilly not to advance FHD-909 into dose expansion, which in turn winds down the collaboration. While disappointing, we believe Foghorn executed well and developed a high-quality SMARCA2 inhibitor that achieved favorable safety and exposure. In our callback, mgmt described the result as unambiguous but more reflective of SMARCA2/4 as a poor target for synthetic lethality. Hence, the collaboration will also not advance a http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Hold/27135958.html Thu, 01 Oct 2026 16:08:35 -0400 FHTX http://www.streetinsider.com/Downgrades/Citizens+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Market+Perform/27135279.html <p>Citizens analyst Silvan Tuerkcan downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Market Outperform to Market Perform.</p><p>The analyst comments "Foghorn Therapeutics and Eli Lilly announced the discontinuation of FHD-909, a SMARCA2-selective inhibitor, following disappointing efficacy signals in a solid tumor dose escalation study. The two companies have ended their research and development collaboration, and FHTX will move out of the chromatin synthetic lethality approach altogether. We move to Market Perform absent near-term catalysts around remaining assets and with shares (including pre-funded warrants) trading at a slight (+26%) premium to cash reserves of $168M (as of 2Q26). We view shares as fairly valued, http://www.streetinsider.com/Downgrades/Citizens+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Market+Perform/27135279.html Thu, 01 Oct 2026 14:55:36 -0400 FHTX http://www.streetinsider.com/Analyst+Comments/Citizens+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Market+Perform/27135279.html <p>Citizens analyst Silvan Tuerkcan downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Market Outperform to Market Perform.</p><p>The analyst comments "Foghorn Therapeutics and Eli Lilly announced the discontinuation of FHD-909, a SMARCA2-selective inhibitor, following disappointing efficacy signals in a solid tumor dose escalation study. The two companies have ended their research and development collaboration, and FHTX will move out of the chromatin synthetic lethality approach altogether. We move to Market Perform absent near-term catalysts around remaining assets and with shares (including pre-funded warrants) trading at a slight (+26%) premium to cash reserves of $168M (as of 2Q26). We view shares as fairly valued, http://www.streetinsider.com/Analyst+Comments/Citizens+Downgrades+Foghorn+Therapeutics+%28FHTX%29+to+Market+Perform/27135279.html Thu, 01 Oct 2026 14:55:36 -0400 FHTX http://www.streetinsider.com/Analyst+PT+Change/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+Stifel/27134389.html <p>Stifel analyst Laura Prendergast lowered the price target on Foghorn Therapeutics (NASDAQ: FHTX) to $5.00 (from $12.00) while maintaining a Buy rating.</p><p>The analyst comments "This morning FHTX announced that they and LLY will not advance SMARCA2 inhibitor (FHD-909) or the selective SMARCA2 degrader program - see PR here. FHTX plans to focus resources on wholly owned pipeline, including: (1) a selective EP300 degrader (IND in later 2027), (2) a novel (target undisclosed) oral I&I program (IND + FPI likely by late 2027), (3) a selective CBP degrader (IND likely not until 2028), and (4) induced proximity platform (BD focus). Pipeline http://www.streetinsider.com/Analyst+PT+Change/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+Stifel/27134389.html Thu, 01 Oct 2026 12:44:26 -0400 FHTX http://www.streetinsider.com/Analyst+Comments/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+Stifel/27134389.html <p>Stifel analyst Laura Prendergast lowered the price target on Foghorn Therapeutics (NASDAQ: FHTX) to $5.00 (from $12.00) while maintaining a Buy rating.</p><p>The analyst comments "This morning FHTX announced that they and LLY will not advance SMARCA2 inhibitor (FHD-909) or the selective SMARCA2 degrader program - see PR here. FHTX plans to focus resources on wholly owned pipeline, including: (1) a selective EP300 degrader (IND in later 2027), (2) a novel (target undisclosed) oral I&I program (IND + FPI likely by late 2027), (3) a selective CBP degrader (IND likely not until 2028), and (4) induced proximity platform (BD focus). Pipeline http://www.streetinsider.com/Analyst+Comments/Foghorn+Therapeutics+%28FHTX%29+PT+Lowered+to+%245+at+Stifel/27134389.html Thu, 01 Oct 2026 12:44:26 -0400 FHTX http://www.streetinsider.com/Corporate+News/Foghorn+cuts+40%25+of+staff+after+FHD-909+trial+falls+short/27131400.html <p>Foghorn Therapeutics Inc. (Nasdaq: FHTX) said it will not advance its FHD-909 cancer drug candidate after a Phase 1 dose escalation trial failed to demonstrate sufficient efficacy, according to a press release from the Watertown, Mass.-based biotechnology company.</p><p>Foghorn and its partner Eli Lilly reviewed clinical data from the trial of FHD-909 (LY4050784), a small molecule that selectively inhibits the SMARCA2 protein, and concluded the drug did not meet the efficacy threshold required to proceed to the clinical development expansion phase. The two companies also decided not to advance a separate selective SMARCA2 degrader program, and do not anticipate further collaboration http://www.streetinsider.com/Corporate+News/Foghorn+cuts+40%25+of+staff+after+FHD-909+trial+falls+short/27131400.html Thu, 01 Oct 2026 07:02:52 -0400 FHTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Foghorn+Therapeutics++++++For%3A+Sep+25/27131386.html si-local-file:///var/storage/secattach/20261001/27131386.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Foghorn+Therapeutics++++++For%3A+Sep+25/27131386.html Thu, 01 Oct 2026 07:01:00 -0400 FHTX http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+Update+on+FHD-909+and+Strategic+Priorities/27131279.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program<br /></em><br /></li><li style="list-style-position:inside; margin-top:5pt; margin-bottom:5pt; text-align:center;"><em>Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform<br /></em><br /></li><li style="list-style-position:inside; margin-top:5pt; margin-bottom:5pt; text-align:center;"><em>Pipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction</em><br /><br /></li></ul> <p>WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+Update+on+FHD-909+and+Strategic+Priorities/27131279.html Thu, 01 Oct 2026 07:00:00 -0400 FHTX http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+Provides+Update+on+FHD-909+and+Strategic+Priorities/27131279.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program<br /></em><br /></li><li style="list-style-position:inside; margin-top:5pt; margin-bottom:5pt; text-align:center;"><em>Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform<br /></em><br /></li><li style="list-style-position:inside; margin-top:5pt; margin-bottom:5pt; text-align:center;"><em>Pipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction</em><br /><br /></li></ul> <p>WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+Provides+Update+on+FHD-909+and+Strategic+Priorities/27131279.html Thu, 01 Oct 2026 07:00:00 -0400 FHTX